Kornimate/medical-research-clean huggingface dataset:
a study of the safety and tolerance of long-term therapy with intravenous cytovene (ganciclovir sodium) for cytomegalovirus retinitis in persons with aids

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to evaluate the safety and tolerance of long-term ganciclovir (dhpg) therapy for newly diagnosed macular threatening cytomegalovirus (cmv) retinitis in aids patients. to evaluate the clinical response to a 52 week course of intravenous dhpg therapy. to evaluate the safety and tolerance of long-term dhpg with concurrent treatment with zidovudine (azt). (patients utilizing treatment with other anti-retroviral drugs will be considered for study entry on a case by case basis.) to determine survival in this group of patients with aids and cmv retinitis.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * topical acyclovir. * selected cytokines. * allowed after the first 4 weeks of ganciclovir: * zidovudine (azt) at a reduced dose (500 mg/day) in patients who have tolerated ganciclovir without grade 3/4 hematological toxicity. * other anti-retrovirals after consultation with the syntex study monitor. patients must have the following: * aids and newly diagnosed cytomegalovirus (cmv) retinitis. * an understanding of the nature of the study, agreement to its provisions, and willingness to sign the informed consent approved by the appropriate institutions review board, and syntex. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * have only peripheral cmv retinitis (defined as a lesion outside the major temporal vascular arcades, greater than 1500 microns from the optic disk, or greater than 3000 microns from the fovea). * ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic retinal assessment. * ocular conditions requiring immediate surgical correction (eg: * retinal tear or detachment). * demonstrated hypersensitivity to acyclovir or ganciclovir. * dementia, decreased mentation or other encephalopathic signs and symptoms which would interfere with the ability of the patient to comply with the protocol. concurrent medication: excluded: * antimetabolites. * alkylating agents. * nucleoside analogs (excluding selected anti-retroviral agents). * imipenem-cilastatin. * interferons. * selected cytokines. * acyclovir (except topical acyclovir). patients with the following are excluded: * have only peripheral cmv retinitis (defined as a lesion outside the major temporal vascular arcades, greater than 1500 microns from the optic disk or greater than 3000 microns from the fovea). * concomitant conditions or diseases described in exclusion co-existing conditions. prior medication: excluded within 1 month of study entry: * previous treatment with anti-cytomegalovirus therapy (e.g., ganciclovir, foscarnet or cmv hyperimmune globulin).

Keywords: retinitis aids-related opportunistic infections ganciclovir drug interactions cytomegalovirus infections acquired immunodeficiency syndrome zidovudine
mesenchymal stem cell injection in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: whether the mesenchymal injection on als patients is effective or not?

after and before transplantation, all of the patients will visit by experience neurologist and evaluate with emg (electromyography) and spirometry procedure and clinical progression of disease.

Eligibility criteria:
inclusion criteria: 1. sporadic als according to escorial criteria 2. onset of disease with spinal cord involvement, less than 3 years of disease onset with disease progression at 6 past months 3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2 in chewing and waking in als-frs and fvc(functional vital capacity) equal or more than 50% of prediction amount 4. normal polysomnography 5. signed consent form exclusion criteria: 1. pregnancy or lactation, 2. vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or hematologic disease 3. hospitalization due to serious illness in the last two months 4. survival time less than two years 5. hypersensitivity to any component used in the cell culture
penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: a phase ii clinical study (alter-l043)

Conditions: Resectable Locally Advanced Non-small Cell Lung Cancer

Summary: this is a multicenter, randomized, open label, phase ii study.

this is a multicenter, randomized, open label, phase ii study assessing the efficacy and safety of penpulimab plus chemotherapy or penpulimab plus anlotinib or penpulimab plus chemotherapy and anlotinib as neoadjuvant/adjuvant treatment in patients with resectable locally advanced non-small cell lung cancer. eligible patients will be randomized to receive either penpulimab (200mg, iv, q3w) plus chemotherapy (platinum based chemotherapy) or penpulimab (200mg, iv, q3w) plus anlotinib (12mg, po, day 1-14, q3w) or penpulimab (200mg, iv, q3w) plus chemotherapy (platinum based chemotherapy) and anlotinib (12mg, po, day 1-14, q3w) in a 1:1:1 ratio.

Eligibility criteria:
inclusion criteria: * early stage iib-iiib (n2), operable non-small cell lung cancer, confirmed in tissue. * epidermal growth factor receptor/anaplastic lymphoma kinase/ros1 gene fusions mutation was negative in primary tumor or lymph node metastasis. * eastern cooperative oncology group (ecog) performance status of 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks. * lung function capacity capable of tolerating the proposed lung surgery. * patients had never received surgery, chemotherapy, radiotherapy or biotherapy. exclusion criteria: * large cell carcinoma and mixed cell lung cancer. * any systemic anti-cancer treatment for nsclc, including cytotoxic drug therapy, immunotherapy, experimental treatment. * prior treatment with local radiotherapy. * prior treatment with any drug that targets t cell co-stimulations pathways (such as checkpoint inhibitors). * prior treatment with antilotinib and other antiangiogenic drugs. * history of hypersensitivity to any active or inactive ingredient of penpulimab, anlotinib or chemotherapy. * patients with multiple factors affecting oral medication (e.g. inability to swallow, chronic diarrhea, and intestinal obstruction, etc.). * past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease. * patients whose tumor has invaded important blood vessels or whose tumor is likely to invade important blood vessels and cause fatal massive hemorrhage during follow-up study. * patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism. * pregnant or lactating women. * history of neurological or mental disorders, including epilepsy or dementia.
monitoring of syncopes and/or sustained palpitations of suspected arrhythmic origin with external loop-recorder (spiderflash)

Conditions: Syncope; Palpitations

Summary: the purpose of this study is to evaluate the diagnostic yield (at 1 month post enrollment) of an external loop recorder (spiderflash-t) in patients with syncope or palpitations of suspected arrhythmic origin, within 30 days before enrollment.

diagnostic yield (primary outcome) definition = number of patients with conclusive diagnosis (as per investigators' decision) over the total number of patients

Eligibility criteria:
inclusion criteria: * syncope and/or palpitations events occurred in the last 30 days * events likely of arrhythmic origin * no conclusive diagnosis established yet * high probability of episodes recurrence (presence of at least one previous event in the last 12 months) * patient has signed the consent to participate to the study and/or to data treatment exclusion criteria: * inability to understand the purpose of the study or refusal to cooperate * expected low compliance with the recording technique. * logistical impossibility to deliver the elr within 30 days after the index event (or after discharge from er and/or hospitalization and/or clinic visit) * already included in other competitor clinical study * under guardianship * age less than 18

Keywords: syncopal events palpitation events
the effect of curcumin for treatment of cancer anorexia-cachexia syndrome in patients with stage iii-iv of head and neck cancer

Conditions: Cancer Cachexia; Head and Neck Cancer; Head and Neck Neoplasms

Summary: a study of curcumin to prevent cancer anorexia and cachexia syndrom in locally advance and advance stage head and neck cancer (stage iii, iv)


Eligibility criteria:
inclusion criteria: * head and neck cancer stage iii-iv * cancer anorexia cachexia syndrome by 2011 cancer cachexia an international consensus * enteral feeding with nasogastric tube or gastrostomy * ecog 0-2 * normal bone marrow, kidneys, and liver function * normal function of enteral digestion and absorption exclusion criteria: * pregnancy * history of allergy to curcumin or herbal medicine * history of herbal medicine used * history of billiary of obstruction * history of antiplatelete or anticoagulant.

Keywords: cancer cachexia head and neck cancer curcumin tumuric cancer anorexia cachexia
optimizing in-hospital use of evidence-based therapies for patients with cardio-renal-metabolic disease

Conditions: Heart Failure; Type 2 Diabetes; Chronic Kidney Diseases

Summary: this study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within duke university medical center. the primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly sglt2 inhibitor therapy. approximately 200 patients meeting eligibility criteria will be included in the study. patients will be assigned into study groups, as defined by randomization of their treating clinician team to receiving the virtual consult versus not.


Eligibility criteria:
inclusion criteria: 1. hospitalized adults age ≥ 18 years with ≥1 of the following diagnoses, as defined by the medical record: 1. hf (any ejection fraction) 2. ckd with estimated gfr ≥ 20 ml/min/1.73m2 \* 3. t2dm (by clinical history or hemoglobin a1c) exclusion criteria: 1. end-stage stage renal disease on dialysis or egfr \<20 ml/kg/1.73m2. 2. pre-menopausal woman who are either breast-feeding or pregnant 3. history of heart transplant or actively listed for heart transplant 4. implanted left ventricular assist device or implant anticipated within 3 months. 5. enrolled in or planning to enroll in hospice care. 6. active cancer (except localized prostate, breast, or non-melanoma skin cancers)

Keywords: heart failure type 2 diabetes chronic kidney disease implementation hospitalization
hemicraniectomy for malignant middle cerebral artery infarction (hemmi)

Conditions: Infarction

Summary: a single-centered, randomized, controlled clinical trial comparing standardized medical care alone with standardized medical care and decompressive hemicraniectomy to determine the effectiveness of decompressive surgery more definitively in patients with clinical signs of infarction of the middle carotid artery (mca) territory.

a single-centered, randomized, controlled clinical trial comparing standardized medical care alone with standardized medical care and decompressive hemicraniectomy to determine the effectiveness of decompressive surgery more definitively in patients with clinical signs of infarction of the mca territory and and who arrived at the hospital within 72 hours of symptom onset.

Eligibility criteria:
inclusion criteria: * patients between 18 to 65 years old who presented with clinical signs of infarction of the mca territory and who arrived at the hospital within 72 hours of symptom onset. other inclusion criteria included a glasgow coma score (gcs) of 6 to14 in patients with right mca infarction or gcs 5 to 9 in patients with left mca infarction (adjusted to account for effect on speech deficit on gcs scores), or gcs of 15 on arrival but subsequently deteriorated neurologically as defined by a score of ≥1 on the level of consciousness item of the national institutes of health stroke scale (nihss);computed tomography (ct) scan of the head showing ischemic changes corresponding to more than 50% of the mca territory with or without involvement of other vascular territories;and written informed consent from the patient or a legal representative. exclusion criteria: * patients with previous disabling neurological disease, an estimated premorbid modified rankin scale (mrs) score \>2; terminal illness; presence of serious medical comorbidities like end-stage renal failure and cardiac disease with severe hemodynamic compromise; infarction due to surgical complications or vasospasm; primary intracranial hemorrhage; coagulopathies; and high risk for surgery upon assessment by the medical team.

Keywords: hemicraniectomy, stroke, decompressive surgery, hemmi
evaluation of multimodal and non-invasive spina bifida neurovessels during prospective follow-up

Conditions: Spina Bifida

Summary: the aim of the study is to investigate known urinary biomarkers in order to determine whether they can be predictive of a risk of damage to the upper urinary tract and therefore the kidneys in patients with spina bifida. the risk of damage to the upper urinary tract can be calculated using the galloway score, based on the results of the urodynamic study and retrograde urethrocystography, which all patients with spina bifida have regularly. the urinary biomarkers studied timp-2 (tissue inhibitor of metalloproteinases 2) and mmp-2 (matrix metalloproteinase-2) are potentially associated with renal degradation, but this has not yet been demonstrated. volunteers to take part in the study will have their biomarkers measured at the time of their urodynamic assessment.


Eligibility criteria:
inclusion criteria: * spina patients consulted as part of the multidisciplinary consultation of the spina bifida rare disease reference centre; * written consent to participate in the research. * compulsory membership of a social security scheme exclusion criteria: * patients with a non-continuous trans ileal urinary diversion ; * patients with enterocystoplasty; * untreated bacteriuria at the time of urodynamic assessment and urine sample collection; * history of urinary tract tumour; * history of histologically proven interstitial cystitis; * persons under legal protection (safeguard of justice, curatorship, guardianship); * persons deprived of their liberty. * women claiming to be pregnant

Keywords: spina bifida urinary biomarker upper urinary tract galloway score urodynamic work-up urethrocystography
study of antioxidants and oxidants in malnourished children

Conditions: Protein-energy Malnutrition; Kwashiorkor; Marasmus

Summary: it is believed that the organs of severely malnourished children malfunction because harmful compounds called oxidants injure the tissues in these organs. in a healthy person oxidants are made harmless because another compound called glutathione neutralizes them. glutathione is made from three amino acids that we get from the protein we eat in our food. we found that malnourished children were not making enough glutathione because they lacked one of these amino acids called cysteine. in this study we determine why malnourished children do not have sufficient cysteine, and we will feed malnourished children a whey-based diet which is rich in cysteine during their treatment to determine whether they will make more glutathione. this in turn may make their organs recover faster. these findings will let us know whether malnourished children can recover faster if they are given more cysteine during the early phase of treatment.


Eligibility criteria:
* infants and toddlers, 6-18 months of age * suffering from severe protein-energy malnutrition, kwashiorkor and marasmic-kwashiorkor

Keywords: glutathione kinetics oxidant damage anti-oxidant capacity oxidative stress cysteine kinetics severe childhood malnutrition
large language models to aid gynecological oncology treatment

Conditions: Breast Cancer

Summary: this trial aims to assess the impact of providing medical students with access to large language models, in comparison to treatment guideline pdfs, on treatment concordance with a conventional multidisciplinary tumor board

advanced artificial intelligence (ai) technologies, particularly large language models such as openai's chatgpt, hold significant potential for enhancing medical decision-making. while chatgpt was not specifically designed for medical applications, it has shown utility in various healthcare scenarios, including answering patient inquiries, drafting medical documentation, and aiding clinical consultations. despite these advancements, its role in supporting treatment decision-making-particularly in complex oncological cases-remains underexplored. treatment decision-making in gynecological oncology is a multifaceted process that integrates evidence-based guidelines, tumor biology, patient-specific factors, and clinical expertise. ai tools like chatgpt could potentially assist in synthesizing relevant guideline-based recommendations, improving decision accuracy, and facilitating more efficient clinical workflows. however, chatgpt is not specifically tailored for oncological treatment decisions and lacks comprehensive validation in this domain. additionally, it may generate misinformation or plausible-sounding but inaccurate recommendations, which could impact clinical judgment. therefore, understanding how medical professionals, including students and early-career physicians, interact with such ai tools is essential before broader integration into clinical practice. locally deployable models, such as llama, enable secure, on-premise usage while retrieval-augmented generation ensures guideline-compliant recommendations. this study will investigate the impact of language models on treatment decision support for medical students managing gynecological oncology cases. this is a crossover study, where participants will be randomized into two groups. all participants begin with access to chatgpt for two vignettes. they then proceed with two cases using either a locally deployed language model, followed by two cases relying on guideline pdfs, or vice versa. each participant will analyze clinical cases, propose treatment plans, and rate their confidence in their decisions and decision support system usability. this study aims to provide insights into the potential benefits and limitations of integrating ai tools like chatgpt into oncological treatment decision-making.

Eligibility criteria:
inclusion criteria: - medical students having started with clinical subjects exclusion criteria: - not being a medical student

Keywords: large language models clinical decision support gynecological oncology
using wireless-technology for feedback of daily walking activity post-stroke

Conditions: Stroke

Summary: regaining independent walking is the top priority for individuals recovering from stroke. thus, physical rehabilitation post-stroke should focus on improving walking function and endurance. however, the amount of walking completed by individuals with stroke attending rehabilitation is far below that required for independent community ambulation. there has been increased interest in accelerometer-based monitoring of walking post-stroke. walking monitoring could be integrated within the goal-setting process for those with ambulation goals in rehabilitation. the purpose of this study is to determine the effect of accelerometer-based feedback of daily walking activity during rehabilitation on the frequency and duration of walking post-stroke.


Eligibility criteria:
inclusion criteria: * individuals with sub-acute stroke attending in-patient rehabilitation at toronto rehab * patients who have identified improving walking function as a rehabilitation goal * patients who can walk without supervision at the time of recruitment into the study
research of biomarkers associated with the diagnosis and severity of bradykinin angioedema

Conditions: Angio Edema

Summary: the unpredictable nature of the attacks is one of the essential characteristics of bradykinin angioedema. the two main difficulties for physicians managing a patient with bradykinin angioedema are to make the diagnosis and anticipate the severity. biomarkers can be used to diagnose, guide treatment, or predict the severity of a disease. however, the identification of biomarkers is currently difficult in bradykinin both for diagnosis and prognosis. while measurement of c4 and c1 inhibitor (quantitative and functional assays) allows the diagnosis of bradykinin angioedema due to c1 inhibitor deficiency, whether genetic or acquired, many patients with normal c1 inhibitor bradykinin angioedema, either hereditary or acquired, are still difficult to diagnose. for patients with hereditary angioedema with c1-inhibitor deficiency, there is no biomarker currently available to predict the severity. any biomarker that could improve the diagnosis on the one hand, and improve the prediction of the frequency and severity of the response to treatment on the other hand, would obviously be extremely useful. the aim of our study is to assess the existence possible biomarkers for diagnosis and prognosis of bradykinin angioedema.


Eligibility criteria:
inclusion criteria: * group 1 : patients with bradykinin angioedema * patient with biologically proven hereditary angioedema with c1 inhibitor deficiency, * or a patient with bradykinin angioedema related to a plasminogen or factor xii mutation, * or patients with bradykinin angioedema related to ace inhibitors or arb2, * or patient with acquired bradykinin angioedema due to c1 inhibitor deficiency, * age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * having a blood collection scheduled as part of routine care * being insured by social security group 2 : patients with histamine-mediated angioedema * patient with idiopathic histamine angioedema as determined by the referring physician * age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * having a blood collection scheduled as part of routine care * being insured by social security exclusion criteria: * minors or protected adults, * pregnant or breastfeeding woman, * person deprived of liberty, * person in an emergency situation, * person having refused or unable to give their non-opposition

Keywords: angioedema bradykinin biomarker biobanking
inpatient mortality prediction algorithm clinical trial (impact)

Conditions: Decompensation, Heart; Decompensation; Heart, Congestive; Death

Summary: through the mapping of retrospective patient data into a discrete multidimensional space, a novel algorithm for homeostatic analysis, was built to make outcome predictions. in this prospective study, the ability of the algorithm to predict patient mortality and influence clinical outcomes, will be investigated.


Eligibility criteria:
inclusion criteria: * all adult patients admitted to the participating units will be eligible. exclusion criteria: * all patients younger than 18 years of age will be excluded.

Keywords: dascena patient mortality machine learning algorithm diagnostic